BVF Inc’s MoonLake Immunotherapeutics MLTX Stock Holding History

BVF Inc’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$298M	Sell	16,001,284 -3,750,000	-19%	-$62.1M	9.5%	2
2025 Q4	$260M	Hold	19,751,284	–	–	8.76%	3
2025 Q3	$142M	Hold	19,751,284	–	–	5.74%	4
2025 Q2	$932M	Hold	19,751,284	–	–	33.31%	1
2025 Q1	$772M	Hold	19,751,284	–	–	31.45%	1
2024 Q4	$1.07B	Sell	19,751,284 -2,000,000	-9%	-$102M	36.25%	1
2024 Q3	$1.1B	Hold	21,751,284	–	–	32.08%	1
2024 Q2	$956M	Hold	21,751,284	–	–	26.81%	1
2024 Q1	$1.09B	Hold	21,751,284	–	–	30.04%	1
2023 Q4	$1.31B	Hold	21,751,284	–	–	32.87%	1
2023 Q3	$1.24B	Hold	21,751,284	–	–	33.43%	1
2023 Q2	$1.11B	Hold	21,751,284	–	–	30.92%	1
2023 Q1	$465M	Hold	21,751,284	–	–	17.01%	1
2022 Q4	$228M	Hold	21,751,284	–	–	9.64%	1
2022 Q3	$173M	Hold	21,751,284	–	–	7.15%	1
2022 Q2	$114M	Buy	+21,751,284	New	+$137M	5.52%	2

Other funds holding MLTX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc's MLTX Position: Q1 2026 in Review

BVF Inc reduced its MoonLake Immunotherapeutics (MLTX) stake by 19% in Q1 2026, selling an estimated $62.1M and leaving 16,001,284 shares worth $298M. The position accounts for 9.5% of the portfolio, ranked #2.

BVF Inc first reported a position in MLTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.31B in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

BVF Inc held 16,001,284 shares of MoonLake Immunotherapeutics worth $298M as of Q1 2026.
BVF Inc sold 3,750,000 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $62.1M.
MoonLake Immunotherapeutics made up 9.5% of BVF Inc's portfolio in Q1 2026, its #2 holding.
BVF Inc first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 16 quarters since.
BVF Inc's MoonLake Immunotherapeutics position peaked at $1.31B in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.